Six hundred eight two (51%) patients’ tumours were assessed for BRAF and NRAS mutation status; BRAF V600 and NRAS mutations were detected in 303 (44%) and 134 (20%) tumours tested. This evidence concerns the gene BRAF and neoplasm.